To those of you who have family members with Fragile X, thank you for being interested in clinical trials! This is a challenging phase for all of us, and as exciting as it is, we know many of you have questions about what it means to be in a clinical trial.
Each study is supervised by a doctor that specializes in Fragile X. These trials are free, you do not have to tell your insurance company, and you can leave any time you want. Travel costs are usually covered.
The FDA requires two successful large-scale clinical trials before it will consider approving a new treatment. If studies are successful and the FDA approves new drugs, others with Fragile X can also have access to these medicines.
Clinical Trials and Studies recruiting patients
Combining Lovastatin and a Parent-Implemented Language Intervention in a Multimodal Treatment for Fragile X Syndrome - UC Davis MIND Institute
The study is testing the efficacy of a multi-modal treatment comprised of the medication lovastatin or placebo, and a Parent-Implemented Language Intervention (PILI) in children and adolescents with FXS between the ages of 10 and 17. Please contact the study coordinator Erika Bickel at email@example.com or (916) 703-0281.
MRI Study in Children with Fragile X Syndrome or Down Syndrome - U Mass Medical Center
Recent Studies Awaiting Results
- 3/2016 - Analysis of Developmental Brain Dysfunction (DBD) in Families with Fragile X Syndrome - sponsored by FRAXA Research Foundation
Principal Investigators: Margaret King and Brenda Finucane, Geisinger Health System.
This study’s goal is to help design future Fragile X clinical trials more effectively and to help predict which potential treatments would be most helpful to individuals.
- 2012-15: Epigallocatechin gallate (mega green tea extract) – Mara Dierssen – Barcelona, Spain. Trial results are being analyzed.
Completed Clinical Trials With Results
- 2/2016 - Double Blind Crossover Trial of Ganaxolone - Investigators: Frank Kooy and Anke Van Dijck- Antwerp, Belgium, sponsored by FRAXA Research Foundation. Dr. Randi Hagerman conducted a part of this trial in Davis, CA, sponsored by Marinus Pharmaceuticals.
"Consistent with the mechanism of action and preclinical studies, anxious FXS patients treated with ganaxolone showed clinically relevant reductions in anxiety across several scales and subscales sensitive to measuring changes in anxious behavior. These results are encouraging and suggest that ganaxolone may improve anxiety in children with FXS, which could potentially allow them, as well as their families, to experience a more stabilized lifestyle." - Frank Kooy, PhD.
- 12/2015 - Neuren’s trofinetide showed some success in small Phase 2 clinical trials in Fragile X syndrome and in Rett Syndrome
- Alcobra's metadoxine trial has completed. Learn more at Clinicaltrials.gov
- 2012-13: Open-Label Pilot Trial of Lovastatin - Francois Corbin, MD, PhD — Sherbrooke, Canada
- 2008: Minocycline trial - Carlo Paribello, MD - Toronto, Canada. Positive results were published
- a pilot lithium trial — Elizabeth Berry-Kravis, MD, PhD, and funded by FRAXA. Positive results were published
- pilot trial of CX516 — Elizabeth Berry-Kravis, and funded by FRAXA.
- Phase III trials of arbaclofen were completed by Seaside Therapeutics but results were disappointing in both Fragile X and autism. However, baclofen is an available drug.
For all Fragile X medication trials visit http://www.clinicaltrials.gov/ct2/results?term=fragile+x
To learn how trials work, visit http://clinicaltrials.gov/ct2/info/understand